Bone Biologics Announces Pricing of $5.0 Million Public Offering
Public Offering Announcement: Bone Biologics Corporation has priced a public offering of 1,250,000 shares of common stock and warrants at $4.00 per share, aiming to raise approximately $5 million for clinical trials and corporate purposes, with potential additional proceeds from warrant exercises.
Company Background and Future Outlook: The company focuses on regenerative medicine for bone, particularly in spinal fusion procedures, and is working on developing its bone graft substitute product while emphasizing that forward-looking statements regarding future performance may vary significantly.
Trade with 70% Backtested Accuracy
Analyst Views on BBLGW
No data
About the author
Bone Biologics Announces Closing of $5.0 Million Public Offering
Public Offering Announcement: Bone Biologics Corporation has completed a public offering of 1,250,000 shares of common stock and accompanying warrants, raising $5 million in gross proceeds, with potential additional proceeds of $10 million from warrant exercises.
Use of Proceeds: The company plans to use the net proceeds for funding clinical trials, maintaining its patent portfolio, and general corporate purposes, while also focusing on regenerative medicine for bone and spinal fusion procedures.
Bone Biologics Files Patent Application for Bone Regeneration Technology
Patent Application Filed: Bone Biologics Corporation has filed a patent application for its novel NELL-1 protein, aimed at treating bone conditions, which could enhance its intellectual property portfolio and support clinical development efforts.
Company Overview: Bone Biologics focuses on regenerative medicine for bone, particularly in spinal fusion procedures, and is collaborating with strategic partners to advance the research and development of its products.